CMDh letter for MAHs for medicinal products containing active ingredients in the form of Mesilates, Isetionates, Tosilates or Besilates (February 2008)

Bridging requirements for formulations in a well-establish use application

In follow up to the publication of the ICH E20 draft Guideline “Adaptive Designs for Clinical Trials” in June 2025, the EWG has also prepared a Step 2 informational presentation.

The ICH Secretariat is pleased to announce the release of Training Modules 1 to 7 on ICH Q2(R2) “Validation of Analytical Procedures” and ICH Q14 “Analytical Procedure Development”.

In follow up to the publication of the ICH M4Q(R2) draft revised Guideline in May 2025, the EWG has also prepared a Step 2 informational presentation.

The ICH E20 draft Guideline on “Adaptive Design for Clinical Trials” has reached Step 2b of the ICH Process on 25 June 2025 and entered the Step 3 public consultation period.

The ICH E21 draft Guideline on “Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials” reached Step 2b of the ICH Process in May 2025 and has entered the consultation period.

IMPLEMENTATION OF THE VARIATIONS FRAMEWORK Marketing authorisation holders (MAHs) and national competent authorities should follow certain principles to facilitate a smooth transition to the new variations framework. Type-IB and II variations (including grouped Type-IA variations) For Type-IB and / or Type-II variations submitted before 15 January 2026:  These types of variations will follow the current [...]

Bilaxten and associated names (bilastine)End of procedure: 03/02/2025Date of publication: 28/05/2025

The Assembly of the International Council for Harmonisation (ICH) met in-person on 13 & 14 May, in Madrid, Spain in parallel of meetings of 11 Working Groups preceded by meetings of the ICH Management Committee and the MedDRA Management Committee.